Analyzing the link between shingles and vascular dementia risk

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate whether individuals with herpes zoster (shingles) have an increased risk of vascular dysfunction and vascular dementia compared to those without the condition. Participants with untreated herpes zoster will undergo a series of six follow-up visits over a year, while a control group without herpes zoster will complete only one visit. The study will collect participant data and biospecimens to analyze the role of pathogenic exosomes in mediating these risks. Standard care will be provided to all participants throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

At the Screening Visit (Visit 1/Day 1), all participants must meet all the following criteria in order to be considered for participation in the study:

1. Be a male or female ≥ 18 years of age.
2. Present to clinic for routine dermatologic evaluation with or without rash.
3. Are willing and able to complete study visits and procedures, and able to effectively communicate with the investigator and other study personnel.
4. Have adequate venous access and are willing to undergo venipuncture for blood draws.
5. Able to provide written informed consent prior to any study procedures. Additional inclusion criteria for Herpes zoster (HZ) participants,
6. Present with acute, vesicle-stage HZ that has not been treated with antiviral therapies
7. Are willing and have reliable transportation to complete additional follow-up visits at 7 days, 1 month, 3 months, 6 months, and 12 months after initial visit for acute HZ.

Exclusion Criteria:

At the Screening Visit (Visit 1/Day 1), participants meeting any of the following criteria will be excluded from participation in the study:

1. Female individuals who are pregnant or breast-feeding.
2. Receiving systemic or topical antivirals for varicella zoster virus (VZV).
3. Sensitivity or allergy to systemic or topical antiviral medications for HZ.
4. History of diagnosed HZ within the last 8 years.
5. Received a HZ vaccine (e.g., Zostavax®/Shingrix®) within the last 8 years.
6. Received any vaccinations within the last 3 months.
7. Currently taking immunosuppressive therapies, including medications and radiation.
8. Currently taking any anticoagulants.
9. History of any coagulation disorder(s).
10. History of end-stage renal disease or uremia.
11. History of end-stage liver disease.
12. History of HIV.
13. Have had a COVID-19 infection in last 3 months.
14. Any history of non-skin cancers within the last 3 months.
15. History of serious infection requiring hospitalization in the last 3 months.
16. Prior history of cardiovascular accident or myocardial infarction within the last 12 months.
17. Prior cerebrovascular accident in the past 12 months.

Where it's running

• Center for Clinical Studies, LTD. LLP
  Houston, Texas, United States Recruiting
• Center for Clinical Studies, LTD. LLP
  Webster, Texas, United States Recruiting

Study contacts

• Study coordinator: Study Principal Investigator
• Email: info@ccstexas.com
• Phone: 281-333-2288

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Digital Dementia Registry Bavaria: a multicenter, long-term registry of people with mild cognitive impairment and dementia and their family caregivers

  This registry will collect long-term health and care data from people with mild cognitive impairment or dementia in Bavaria and their caregivers to understand how dementia progresses and how care is provided.

  Recruiting at 12 sites University of Erlangen-Nürnberg Medical School · Aschaffenburg and 11 other locations · NCT07721701

• Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes

  This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.

  Recruiting Center for Eye Research Australia · Melbourne, Victoria · NCT07545473

• What predicts emergency department visits in frail older adults

  This project tests whether a blood marker (plasma pTau181) and signs of cerebrovascular damage can help predict which non-autonomous older adults will need to return to the emergency department within six months.

  Recruiting University of Pisa · Pisa, Pisa · NCT07259499

• Treatment for Herpes Zoster Pain Using Dexmedetomidine and High Voltage Therapy

  This study is testing whether a nasal spray with dexmedetomidine, used alongside high-voltage therapy, can help people with painful herpes zoster feel better.

  Recruiting Phase 2 Zunyi Medical College · Zunyi, Guizhou · NCT06978192

• Comparing Pregabalin and Lacosamide for Pain Relief in Shingles Patients

  This study is testing whether Pregabalin or Lacosamide works better to relieve pain in adults aged 18 to 50 who have post-herpetic neuralgia after shingles.

  Recruiting CMH Kharian Medical College · Kharan, Punjab Province · NCT06969417

• Two-dose recombinant shingles vaccine for healthy adults 40 and older

  This trial will try two doses of a recombinant shingles vaccine in healthy adults aged 40 and over to see how safe it is and whether it produces an immune response.

  Recruiting Phase 1/2 Shanghai Institute Of Biological Products · Wuhan, Hubei · NCT06932523

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.